Business
Total Voting Rights
Fusion Antibodies plc has announced its total voting rights, stating that as of January 30, 2026, the company's issued share capital consists of 125,021,878 ordinary shares of 4 pence each, with each share carrying one voting right. The company holds no shares in treasury, meaning the total number of voting rights available to shareholders is 125,021,878, which will serve as the denominator for FCA Disclosure Guidance and Transparency Rules calculations. Disclaimer*
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\n30 January 2026\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nTotal Voting Rights\n \nFusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the issued share capital of the Company at the date of this announcement comprises 125,021,878 ordinary shares of 4 pence each with one voting right per share (\"Ordinary Shares\"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 125,021,878.\n \nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \nEnquiries: \n \n\n\n\n\nFusion Antibodies plc\n\n\n www.fusionantibodies.com\n\n\n\n\nAdrian Kinkaid, Chief Executive Officer\nStephen Smyth, Chief Financial Officer\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nFusion Antibodies interactive investor hub\n\n\nhttps://investorhub.fusionantibodies.com/\n\n\n\n\n \n\n\n\n\n\n\n\nAllenby Capital Limited\n\n\nTel: +44 (0) 20 3328 5656 \n\n\n\n\nJames Reeve/Vivek Bhardwaj (Corporate Finance)\nTony Quirke/Joscelin Pinnington (Sales and Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nShard Capital Partners LLP\n\n\n\n\n\n\n\nDamon Heath (Joint Broker)\n\n\nTel: +44 (0) 207 186 9952\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nWalbrook PR\n\n\n Tel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n Mob: +44 (0)7876 741 001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAbout Fusion Antibodies plc\n \nFusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers an integrated end-to-end range of antibody discovery, engineering and expression serv...